Benefits
Modest blood pressure reduction in hypertension (meta-analysis)
Yi 2022 meta-analysis (Front Endocrinol, 7 trials, 212 study arms) showed sesamin supplementation significantly reduced systolic blood pressure but did not affect diastolic BP, weight, HDL-c, or triglycerides. showed 4-week sesamin 60 mg/day significantly reduced both systolic and diastolic BP in mildly hypertensive humans (n=25, double-blind, crossover). Effect size approaches that of low-dose ACE inhibitor.
Lipid profile improvements
Yi 2022 meta-analysis showed sesamin supplementation significantly reduced total cholesterol and LDL-c. Hirata 1996 (Atherosclerosis) showed sesame lignan reduced cholesterol in humans. Effect is more pronounced in subjects with elevated baseline cholesterol; less consistent in normocholesterolemic individuals. Sesame oil components may contribute additionally via gamma-tocopherol preservation.
20-HETE inhibition (vasoactive metabolite)
Wu 2009 crossover RCT (n=33 overweight) showed 25 g/d sesame for 5 weeks reduced plasma 20-HETE by 28% and urinary 20-HETE by 32% (P<0.001) via CYP4F2 inhibition. 20-HETE is implicated in hypertension pathogenesis, providing mechanistic explanation for sesamin's BP-lowering effect. Although BP unchanged in this short trial, 20-HETE reduction is a relevant downstream target.
Antioxidant capacity enhancement (vitamin E sparing)
Sesamin inhibits CYP4F2-mediated metabolism of α- and γ-tocopherol, preserving vitamin E levels and antioxidant capacity. Sesame seed/oil consumption reliably increases plasma γ-tocopherol — particularly relevant since γ-tocopherol has unique anti-inflammatory effects on RNS. Black sesame meal reduced MDA and increased GSH/total antioxidant capacity.
Mechanism of action
CYP4F2 inhibition (vitamin E preservation + 20-HETE reduction)
Sesamin selectively inhibits cytochrome P450 4F2 (IC50 ~1.9 μM) — the enzyme responsible for both ω-hydroxylation of α/γ-tocopherol (degrading vitamin E) and synthesis of 20-hydroxyeicosatetraenoic acid (20-HETE) from arachidonic acid. Selective vs CYP4A11 (IC50 >150 μM). The dual effect: (a) increases tissue vitamin E, (b) reduces 20-HETE, a vasoconstrictor implicated in hypertension. This is the central biochemical mechanism.
ACE inhibition and eNOS upregulation
Sesame lignans (sesamin, sesamolin) inhibit angiotensin-converting enzyme (ACE) and enhance endothelial nitric oxide synthase (eNOS) activity, promoting vasodilation and blood pressure regulation. Animal studies (Nakano, Iwasa) show sesamin metabolites induce endothelial NO-dependent vasorelaxation independent of antioxidant effect.
NADPH oxidase downregulation in vasculature
Sesamin downregulates NADPH oxidase subunits (p22-phox, p47-phox, gp91-phox) in vascular smooth muscle and endothelium of hypertensive animals, reducing vascular ROS production and improving endothelial function. Acts in concert with eNOS upregulation to restore vascular health.
Hepatic fatty acid oxidation enhancement
Sesamin is a potent inducer of hepatic fatty acid oxidation enzymes (Ashakumary 1999) — particularly carnitine palmitoyltransferase, β-oxidation enzymes, and PPAR-α target genes. Mechanistic basis for hepatoprotective effects in fatty liver models and may contribute to lipid profile improvements observed clinically.
Clinical trials
Double-blind, crossover, placebo-controlled trial (Miyawaki T, Aono H, Toyoda-Ono Y, Maeda H, Kiso Y, J Nutr Sci Vitaminol (Tokyo) 55(1):87-91, doi:10.3177/jnsv.55.87).
25 middle-aged subjects with mild hypertension. Divided into two groups matched by age and BMI. Crossover design with 60 mg/day sesamin or placebo for 4 weeks each.
Sesamin 60 mg/day for 4 weeks significantly reduced systolic and diastolic blood pressure in mildly hypertensive humans. Effect was clinically meaningful (multiple mmHg reduction). Established the 60 mg/day dose as effective for BP modulation. Foundational trial cited in subsequent pooled analyses and guidelines on sesame-derived BP support.
Randomized controlled crossover trial (Wu JH, Hodgson JM, Puddey IB, Belski R, Burke V, Croft KD 2009, Hypertension 54(5):1151-1158 / Nutr Metab Cardiovasc Dis 19(11):774-780, doi:10.1161/HYPERTENSIONAHA.109.139352).
33 overweight men and women in randomized controlled crossover. 25 g/d sesame (~50 mg/d sesame lignan) or isocaloric matched control for 5 weeks each.
Sesame supplementation reduced plasma 20-HETE by 28% (P<0.001) and urinary 20-HETE by 32% (P<0.001). In vitro: sesamin inhibited human renal and liver microsome 20-HETE synthesis (IC50 1.9 μM CYP4F2 vs >150 μM CYP4A11 — highly selective). Urinary sodium, potassium, and BP unchanged in this short overweight cohort. First human evidence that sesame inhibits CYP4F2-mediated 20-HETE synthesis, validating mechanistic basis for BP effect observed in.
Pilot clinical trial (Wichitsranoi J, Weerapreeyakul N, Boonsiri P, Settasatian C, Settasatian N, Komanasin N, Sirijaichingkul S, Khampitak T, Tangrassameeprasert R, Nutr J 10:82, doi:10.1186/1475-2891-10-82).
Pre-hypertensive humans randomized to 2.5 g/day black sesame meal capsules vs placebo for 4 weeks.
Black sesame meal significantly reduced systolic blood pressure and increased plasma vitamin E (γ-tocopherol). Reduced malondialdehyde (lipid peroxidation marker) and increased reduced glutathione, indicating improved oxidative stress balance. Provides additional support for sesame lignan effects on BP and antioxidant status in pre-hypertensive populations.